Harmonizing Quality Improvement Metrics Across Global Trial Networks to Advance Paediatric Clinical Trials Delivery

Author:

Attar Sabah,Price Angie,Hovinga Collin,Stewart Breanne,Lacaze-Masmonteil Thierry,Bonifazi Fedele,Turner Mark A.,Fernandes Ricardo M.

Abstract

Abstract Background Despite global efforts to improve paediatric clinical trials, significant delays continue in paediatric drug approvals. Collaboration between research networks is needed to address these delays. This paper is a first step to promote interoperability between paediatric networks from different jurisdictions by comparing drivers for, and content of, metrics about clinical trial conduct. Methods Three paediatric networks, Institute for Advanced Clinical Trials for Children, the Maternal Infant Child and Youth Research Network and conect4children, have each developed metrics to address delays and create efficiencies. We identified the methodology by which each network identified metrics, described the metrics of each network, and mapped consistency to come to consensus about core metrics that networks could share. Results Metric selection was driven by site quality improvement in one network (11 metrics), by network performance in one network (13 metrics), and by both in one network (five metrics). The domains of metrics were research capacity/capability, site identification/feasibility, trial start-up, and recruitment/enrolment. The network driven by site quality improvement did not have indicators for capacity/capability or identification/feasibility. Fifteen metrics for trial start up and conduct were identified. Metrics related to site approvals were found in all three networks. The themes for metrics can inform the development of ‘shared’ metrics. Conclusion We found disparity in drivers, methodology and metrics. Tackling this disparity will result in a unified approach to addressing delays in paediatric drug approvals. Collaborative work to define inter-operable metrics globally is outlined.

Funder

Innovative Medicines Initiative

Canadian Institute for Health Research

Food and Drug Administration

Publisher

Springer Science and Business Media LLC

Reference22 articles.

1. Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016. https://doi.org/10.1542/peds.2016-0223.

2. Brewster R, et al. Early discontinuation, results reporting, and publication of pediatric clinical trials. Pediatrics. 2022. https://doi.org/10.1542/peds.2021-052557.

3. IOM (Institute of Medicine). Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020: workshop summary. Washington: The National Academies Press; 2012.

4. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation. Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop. Shore C, Gee AW, Wizemann T, editors. Washington (DC): National Academies Press (US); 2021

5. Turner MA, et al. European research networks to facilitate drug research in children. Br J Clin Pharmacol. 2022;88(10):4258–66.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3